New research links type 2 diabetes and genetic risk to MASLD cirrhosis before 50, warning age-based fibrosis scores can miss severe disease.
|Articles|March 21, 2014
Your Thoughts on Exam-Room Cell Phones?
Please use the comment box to tell us more about how you deal with distraction in the examination room.
Advertisement
You just voted Yes, or No, or It Depends on whether you ask patients to at least turn off the sound on their cell phones while in the exam room.
Please take a moment to add a comment on your cell phone policy, how it’s working, etc, and if you want, share a story with your colleagues about a particular situation in your practice. Thank you.
Advertisement
Related to this article
FDA updates sotatercept-csrk label with HYPERION data, showing earlier use cuts PAH clinical worsening risk 76% alongside background therapy.
A US laboratory study found that 29.5% of patients with Lyme antibodies were seropositive for at least 1 other tick-borne pathogen.
Lumateperone reduced acute mania symptoms by day 3 in a phase 3 bipolar 1 trial, according to Johnson & Johnson.
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
Finerenone wins FDA clearance for type 1 diabetes–related CKD, lowering albuminuria in FINE-ONE and opening a long-awaited treatment path.
New American Society of Hematology guidelines raise ferritin cutoffs to catch iron deficiency sooner, including pregnancy and inflammation, and add TSAT for clearer diagnosis.
The US FDA cleared a novel insulin patch pump that can be used for up to 3 days with an additional 12-hour grace period in persons with diabetes.
Advertisement
Advertisement
Trending on Patient Care Online
1
Individualizing Obesity Treatment in Primary Care: An Expert Discussion
2
Type 2 Diabetes, Genetic Risk Linked to MASLD Cirrhosis Before Age 50
3
FDA Approves Sotatercept-csrk Label Update for Newly Diagnosed PAH
4
Lumateperone Reduces Acute Mania Symptoms in Phase 3 Bipolar I Trial
5